Identification of genetic loci associated with nocturnal enuresis: a genome-wide association study.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Jørgensen, Cecilie SHorsdal, Henriette T
Rajagopal, Veera M
Grove, Jakob
Als, Thomas D
Kamperis, Konstantinos
Nyegaard, Mette
Walters, G Bragi
Eðvarðsson, Viðar Örn
Stefánsson, Hreinn
Nordentoft, Merete
Hougaard, David Michael
Werge, Thomas
Mors, Ole
Mortensen, Preben Bo
Agerbo, Esben
Rittig, Søren
Stefánsson, Kári
Børglum, Anders D
Demontis, Ditte
Christensen, Jane H
Issue Date
2021-01-15
Metadata
Show full item recordCitation
Jørgensen CS, Horsdal HT, Rajagopal VM, Grove J, Als TD, Kamperis K, Nyegaard M, Walters GB, Eðvarðsson VÖ, Stefánsson H, Nordentoft M, Hougaard DM, Werge T, Mors O, Mortensen PB, Agerbo E, Rittig S, Stefánsson K, Børglum AD, Demontis D, Christensen JH. Identification of genetic loci associated with nocturnal enuresis: a genome-wide association study. Lancet Child Adolesc Health. 2021 Mar;5(3):201-209. doi: 10.1016/S2352-4642(20)30350-3.Abstract
Background: Nocturnal enuresis (bedwetting) is a common disorder affecting 10-16% of 7-year-old children globally. Nocturnal enuresis is highly heritable, but its genetic determinants remain unknown. We aimed to identify genetic variants associated with nocturnal enuresis and explore its genetic architecture and underlying biology. Methods: We did a genome-wide association study (GWAS) of nocturnal enuresis. Nocturnal enuresis cases were identified in iPSYCH2012, a large Danish population-based case cohort established to investigate mental disorders, on the basis of 10th revision of the International Statistical Classification of Diseases (ICD-10) diagnoses and redeemed desmopressin prescriptions in Danish registers. The GWAS was done in a genetically homogeneous sample of unrelated individuals using logistic regression with relevant covariates. All genome-wide significant variants were analysed for their association with nocturnal enuresis in an independent Icelandic sample from deCODE genetics. Standardised polygenic risk scores for attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder were constructed from summary statistics of large GWASs and analysed for association with nocturnal enuresis. Findings: The GWAS included 3882 nocturnal enuresis cases and 31 073 controls. We found two loci at chromosome 6 and chromosome 13 significantly associated with nocturnal enuresis. Six genetic variants at the two loci (five variants at chromosome 6q16.2 and one variant at chromosome 13q22.3) surpassed the threshold for genome-wide significance (p<5 × 10-8). There were two lead variants: rs9376454 (chromosome 6q16.2), with an odds ratio (OR) of 1·199 (95% CI 1·135-1·267; p=9·91 × 10-11), and rs60721117 (chromosome 13q22.3), with an OR of 1·149 (1·095-1·205; p=1·21 × 10-8). All associated variants in the chromosome 6 locus were replicated (p<8 × 10-3) in the independent Icelandic cohort of 5475 nocturnal enuresis cases and 303 996 controls, whereas the associated variant in the chromosome 13 locus showed nominal significant association (p=0·031). The percentage of nocturnal enuresis phenotypic variance explained by the common genetic variants was 23·9-30·4%. Polygenic risk for ADHD was associated with nocturnal enuresis (OR 1·06, 95% CI, 1·01-1·10; p=0·011). Among the potential nocturnal enuresis risk genes mapped, PRDM13 and EDNRB have biological functions associated with known pathophysiological mechanisms in nocturnal enuresis, and SIM1 regulates the formation of the hypothalamic neuroendocrine lineage that produces arginine vasopressin, a well known nocturnal enuresis drug target. Interpretation: This study shows that common genetic variants contribute considerably to nocturnal enuresis, and it identifies potential nocturnal enuresis risk genes with roles in sleep, urine production, and bladder function. Given that available treatments target these mechanisms, any of the identified genes and their functional gene networks are potential drug targets.Description
To access publisher's full text version of this article click on the hyperlink belowAdditional Links
https://www.sciencedirect.com/science/article/pii/S2352464220303503Rights
Copyright © 2021 Elsevier Ltd. All rights reserved.ae974a485f413a2113503eed53cd6c53
10.1016/S2352-4642(20)30350-3
Scopus Count
Collections
Related articles
- Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.
- Authors: Cross-Disorder Group of the Psychiatric Genomics Consortium.
- Issue date: 2013 Apr 20
- Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis.
- Authors: Berkenwald A, Pires J, Ellsworth P
- Issue date: 2016 Aug
- Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis.
- Authors: Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, Fossdal R, Stefansson H, Stefansson K, Magnusson P, Gudmundsson OO, Gustafsson O, Holmans P, Owen MJ, O'Donovan M, Thapar A
- Issue date: 2010 Oct 23
- Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
- Authors: Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium.
- Issue date: 2017
- Nocturnal enuresis: a suggestive endophenotype marker for a subgroup of inattentive attention-deficit/hyperactivity disorder.
- Authors: Elia J, Takeda T, Deberardinis R, Burke J, Accardo J, Ambrosini PJ, Blum NJ, Brown LW, Lantieri F, Berrettini W, Devoto M, Hakonarson H
- Issue date: 2009 Aug